title: An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
abstract: Neonatal immune responses to infection and vaccination are biased toward TH2 at the cost of proinflammatory TH1 responses needed to combat intracellular pathogens. However, upon appropriate stimulation, the neonatal immune system can induce adult-like TH1 responses. Here we report that a new class of vaccine adjuvant is especially well suited to enhance early life immunity. The GVI3000 adjuvant is a safe, nonpropagating, truncated derivative of Venezuelan equine encephalitis virus that targets dendritic cells (DCs) in the draining lymph node (DLN) and produces intracellular viral RNA without propagating to other cells. RNA synthesis strongly activates the innate immune response so that in adult animals, codelivery of soluble protein antigens induces robust humoral, cellular, and mucosal responses. The adjuvant properties of GVI3000 were tested in a neonatal BALB/c mouse model using inactivated influenza virus (iFlu). After a single immunization, mice immunized with iFlu with the GVI3000 adjuvant (GVI3000-adjuvanted iFlu) had significantly higher and sustained influenza virus-specific IgG antibodies, mainly IgG2a (TH1), compared to the mice immunized with antigen only. GVI3000 significantly increased antigen-specific CD4(+) and CD8(+) T cells, primed mucosal immune responses, and enhanced protection from lethal challenge. As seen in adult mice, the GVI3000 adjuvant increased the DC population in the DLNs, caused activation and maturation of DCs, and induced proinflammatory cytokines and chemokines in the DLNs soon after immunization, including gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), granulocyte colony-stimulating factor (G-CSF), and interleukin 6 (IL-6). In summary, the GVI3000 adjuvant induced an adult-like adjuvant effect with an influenza vaccine and has the potential to improve the immunogenicity and protective efficacy of new and existing neonatal vaccines.
  
  
  OBJECTIVE
  The suboptimal immune responses in early life constitute a significant challenge for vaccine design. Here we report that a new class of adjuvant is safe and effective for early life immunization and demonstrate its ability to significantly improve the protective efficacy of an inactivated influenza virus vaccine in a neonatal mouse model. The GVI3000 adjuvant delivers a truncated, self-replicating viral RNA into dendritic cells in the draining lymph node. Intracellular RNA replication activates a strong innate immune response that significantly enhances adaptive antibody and cellular immune responses to codelivered antigens. A significant increase in protection results from a single immunization. Importantly, this adjuvant also primed a mucosal IgA response, which is likely to be critical for protection during many early life infections.
authors.affiliation: Global Vaccines Inc., Research Triangle Park, North Carolina, USA Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Syed Muaz
authors.initials: SM
authors.lastname: Khalil
authors.affiliation: Global Vaccines Inc., Research Triangle Park, North Carolina, USA.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Tonkin
authors.affiliation: Global Vaccines Inc., Research Triangle Park, North Carolina, USA.
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Snead
authors.affiliation: Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
authors.forename: Griffith D
authors.initials: GD
authors.lastname: Parks
authors.affiliation: Global Vaccines Inc., Research Triangle Park, North Carolina, USA.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Johnston
authors.affiliation: Global Vaccines Inc., Research Triangle Park, North Carolina, USA ljwhite@globalvaccines.org.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: White
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000524:Alphavirus / Q000276:immunology*; D000818:Animals; D000831:Animals, Newborn / Q000276:immunology / Q000821:virology; D000914:Antibodies, Viral / Q000276:immunology*; D000917:Antibody Formation / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D002460:Cell Line; D002522:Chlorocebus aethiops / Q000276:immunology / Q000821:virology; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D056724:Immunity, Humoral / Q000276:immunology; D018928:Immunity, Mucosal / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000276:immunology; D014709:Vero Cells / Q000276:immunology / Q000821:virology
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D016207:Cytokines; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated